NCT05981183
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
At risk: Primary completion moved at least 2 years later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jan 7, 2026 to Jan 31, 2028
- Eligibility criteria expanded, about 12 words
- Minor Start date: Oct 15, 2023 to Aug 9, 2023v7
- Notable Start date: Aug 7, 2023 to Oct 15, 2023v6
- Minor Primary and study completion dates: Aug 7, 2025 to Jan 7, 2026v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention A, the pulse width = 250 μs, and frequency = 50 Hz.
Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention B, the pulse width = 300 μs, frequency = 25 Hz.
Devices: Transcutaneous electrical nerve stimulation unit (TENS)
Sites
1 site in 1 country
- NYU Langone HealthNew York, New York, United States